20 June 2013
Keywords: novartis, licenses, antisoma, as1404, deal, worth, up
Article | 23 April 2007
Antisoma has signed an exclusive global licensing agreement with Swiss drug major Novartis for its vascular disrupting agent AS1404, in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 April 2007
19 June 2013
© 2013 thepharmaletter.com